Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) lost -0.53 Percent and closed its previous trading session at $1.89. The stock traded with the average Volume of 6.9 Million at the end of last session.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) has the Market Capitalization of 446.06 Million. The Stock has its 52-week High of $7.15 and 52-Week Low of $1.68 and it touched its 52-week high on 01/31/17 and 52-Week Low on 11/15/17.
The company reported its last earnings Actual EPS of $-0.22/share. While, the analyst predicted that the company could provide an EPS of $-0.28/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.06/share which shows an Earnings Surprise of 21.4 Percent.
Sell side analysts plays vital role in buying and selling a stock where 5 analysts rated Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -12.28% where SMA50 and SMA200 are -28.39% and -49% respectively.
The company shows its Return on Assets (ROA) value of -195.9%. The Return on Equity (ROE) value stands at -540.2%.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) currently has a Weekly Volatility of 6.22% percent while its Monthly Volatility is at 8.42% percent. While talking about Performance of the Stock, Synergy Pharmaceuticals, Inc. currently has a Weekly performance of -5.03%, monthly performance percentage is -37 percent, Quarterly performance is -37.21 percent, 6 months performance shows a percent value of -52.87% and Yearly Performance is -66.31 percent.
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.